Cardiovascular Diseases Clinical Trial
— eHLOfficial title:
Improving Patients With Chronic Disease to Engage in the eHealth Care Environment: the Application and Evaluation of eHealth Literacy Concept
Verified date | December 2021 |
Source | National Yang Ming University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to explore the effectiveness of experience learning program of eHealth care to improve the chronic patients' eHL in engaging with the eHealth care system on the indicators on eHealth literacy, patient health engagement, e-Health usage status among Chronic disease patients included type 2 diabetes patients, Chronic kidney disease, and Cardiovascular Diseases.
Status | Completed |
Enrollment | 92 |
Est. completion date | November 15, 2021 |
Est. primary completion date | July 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed as a type 2 diabetes patients, Chronic kidney disease, and Cardiovascular Diseases more than three months. - At least 20 years old, with clear consciousness and able to communicate in Mandarin or Taiwanese. - Possess a mobile phone or tablet with internet capabilities. - Consent to participate in this research and be willing to sign a consent form. Exclusion Criteria: - Suffering from serious diseases, such as: general paralysis, mental disorders, cognitive function abnormalities, etc. - Those who cannot communicate in Mandarin or Taiwanese. - Those who refuse to participate in this research. |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Yang Ming University | Taipei City |
Lead Sponsor | Collaborator |
---|---|
National Yang Ming University |
Taiwan,
Alpay L, van der Boog P, Dumaij A. An empowerment-based approach to developing innovative e-health tools for self-management. Health Informatics J. 2011 Dec;17(4):247-55. doi: 10.1177/1460458211420089. — View Citation
Graffigna G, Barello S, Bonanomi A, Lozza E. Measuring patient engagement: development and psychometric properties of the Patient Health Engagement (PHE) Scale. Front Psychol. 2015 Mar 27;6:274. doi: 10.3389/fpsyg.2015.00274. eCollection 2015. — View Citation
Kayser L, Karnoe A, Furstrand D, Batterham R, Christensen KB, Elsworth G, Osborne RH. A Multidimensional Tool Based on the eHealth Literacy Framework: Development and Initial Validity Testing of the eHealth Literacy Questionnaire (eHLQ). J Med Internet Re — View Citation
Kayser L, Kushniruk A, Osborne RH, Norgaard O, Turner P. Enhancing the Effectiveness of Consumer-Focused Health Information Technology Systems Through eHealth Literacy: A Framework for Understanding Users' Needs. JMIR Hum Factors. 2015 May 20;2(1):e9. doi — View Citation
Knight E, Stuckey MI, Petrella RJ. Health promotion through primary care: enhancing self-management with activity prescription and mHealth. Phys Sportsmed. 2014 Sep;42(3):90-9. doi: 10.3810/psm.2014.09.2080. — View Citation
Kreps GL, Neuhauser L. New directions in eHealth communication: opportunities and challenges. Patient Educ Couns. 2010 Mar;78(3):329-36. doi: 10.1016/j.pec.2010.01.013. Epub 2010 Mar 3. Review. — View Citation
Richtering SS, Morris R, Soh SE, Barker A, Bampi F, Neubeck L, Coorey G, Mulley J, Chalmers J, Usherwood T, Peiris D, Chow CK, Redfern J. Examination of an eHealth literacy scale and a health literacy scale in a population with moderate to high cardiovasc — View Citation
Schillinger D. The Intersections Between Social Determinants of Health, Health Literacy, and Health Disparities. Stud Health Technol Inform. 2020 Jun 25;269:22-41. doi: 10.3233/SHTI200020. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline of eHealth Literacy Questionnaire scores | Evaluate the patient's eHL level, including 7 dimensions (1) Using technology to process health information, (2) Understanding of health concepts and languages, (3)Ability to actively engage with digital service, (4)Feel safe and in control, (5) Motivated to engage with digital service, (6) Access to digital services that work (7)Digital services that suit individual. The higher the score, the better the eHL. | The pretest is completed when the patients agrees to join the intervention. | |
Primary | The eHealth Literacy Questionnaire scores at the end of intervention | Evaluate the patient's eHL level, including 7 dimensions (1) Using technology to process health information, (2) Understanding of health concepts and languages, (3)Ability to actively engage with digital service, (4)Feel safe and in control, (5) Motivated to engage with digital service, (6) Access to digital services that work (7)Digital services that suit individual. The higher the score, the better the eHL. | The post-test 1 is completed at the end of the 6 weeks intervention | |
Primary | The eHealth Literacy Questionnaire scores after intervention at 3 months | Evaluate the patient's eHL level, including 7 dimensions (1) Using technology to process health information, (2) Understanding of health concepts and languages, (3)Ability to actively engage with digital service, (4)Feel safe and in control, (5) Motivated to engage with digital service, (6) Access to digital services that work (7)Digital services that suit individual. The higher the score, the better the eHL. | The post-test 2 is completed after intervention at 3 months | |
Primary | The eHealth Literacy Questionnaire scores after intervention at 6 months | Evaluate the patient's eHL level, including 7 dimensions (1) Using technology to process health information, (2) Understanding of health concepts and languages, (3)Ability to actively engage with digital service, (4)Feel safe and in control, (5) Motivated to engage with digital service, (6) Access to digital services that work (7)Digital services that suit individual. The higher the score, the better the eHL. | The post-test 3 is completed after intervention at 6 months | |
Primary | Baseline of The acceptance of eHealth care scores | The scale was developed base on Technology Acceptance Model to assess patients' behaviors intention of using the eHealth device | The pretest is completed when the patients agrees to join the intervention. | |
Primary | The acceptance of eHealth care scores at the end of intervention | The scale was developed base on Technology Acceptance Model to assess patients' behaviors intention of using the eHealth device | The post-test 1 is completed at the end of the 6 weeks intervention | |
Primary | The acceptance of eHealth care scores after intervention at 3 months | The scale was developed base on Technology Acceptance Model to assess patients' behaviors intention of using the eHealth device | The post-test 2 is completed after intervention at 3 months | |
Primary | The acceptance of eHealth care scores after intervention at 6 months | The scale was developed base on Technology Acceptance Model to assess patients' behaviors intention of using the eHealth device | The post-test 3 is completed after intervention at 6 months | |
Primary | Baseline of Health Technology Usage Sore | Use self-developed structured questionnaires to investigate the types of health technology use and monitoring items. Use types include computer or network systems, mobile apps, health monitoring systems or wearable devices (such as pedometers, smart bracelets, heart rate monitors, blood pressure monitors, Blood glucose meter, blood pressure meter, blood glucose meter or weight scale, etc.) or other, monitoring items include blood pressure, blood sugar, weight, diet, sleep, heart rate, steps or other health data. The higher the number, the more items are monitored, the total score The higher the level, the better the use of health technology. | The pretest is completed when the patients agrees to join the intervention. | |
Primary | The Health Technology Usage Sore at the end of intervention | Use self-developed structured questionnaires to investigate the types of health technology use and monitoring items. Use types include computer or network systems, mobile apps, health monitoring systems or wearable devices (such as pedometers, smart bracelets, heart rate monitors, blood pressure monitors, Blood glucose meter, blood pressure meter, blood glucose meter or weight scale, etc.) or other, monitoring items include blood pressure, blood sugar, weight, diet, sleep, heart rate, steps or other health data. The higher the number, the more items are monitored, the total score The higher the level, the better the use of health technology. | The post-test 1 is completed at the end of the 6 weeks intervention | |
Primary | The Health Technology Usage Sore after intervention at 3 months | Use self-developed structured questionnaires to investigate the types of health technology use and monitoring items. Use types include computer or network systems, mobile apps, health monitoring systems or wearable devices (such as pedometers, smart bracelets, heart rate monitors, blood pressure monitors, Blood glucose meter, blood pressure meter, blood glucose meter or weight scale, etc.) or other, monitoring items include blood pressure, blood sugar, weight, diet, sleep, heart rate, steps or other health data. The higher the number, the more items are monitored, the total score The higher the level, the better the use of health technology. | The post-test 2 is completed after intervention at 3 months | |
Primary | The Health Technology Usage Sore after intervention at 6 months | Use self-developed structured questionnaires to investigate the types of health technology use and monitoring items. Use types include computer or network systems, mobile apps, health monitoring systems or wearable devices (such as pedometers, smart bracelets, heart rate monitors, blood pressure monitors, Blood glucose meter, blood pressure meter, blood glucose meter or weight scale, etc.) or other, monitoring items include blood pressure, blood sugar, weight, diet, sleep, heart rate, steps or other health data. The higher the number, the more items are monitored, the total score The higher the level, the better the use of health technology. | The post-test 3 is completed after intervention at 6 months | |
Primary | Baseline of Patient Health Engagement score | The scale is thought of as a self-administering tool by the patient in order to diagnose his/ her This scale has a total of 5 questions. The higher the number, the higher the patient engagement it is. | The pretest is completed when the patients agrees to join the intervention. | |
Primary | The Patient Health Engagement score at the end of the intervention | The scale is thought of as a self-administering tool by the patient in order to diagnose his/ her This scale has a total of 5 questions. The higher the number, the higher the patient engagement it is. | The post-test 1 is completed at the end of the 6 weeks intervention | |
Primary | The Patient Health Engagement score after intervention at 3 months | The scale is thought of as a self-administering tool by the patient in order to diagnose his/ her This scale has a total of 5 questions. The higher the number, the higher the patient engagement it is. | The post-test 2 is completed after intervention at 3 months | |
Primary | The Patient Health Engagement score after intervention at 6 months | The scale is thought of as a self-administering tool by the patient in order to diagnose his/ her This scale has a total of 5 questions. The higher the number, the higher the patient engagement it is. | The post-test 3 is completed after intervention at 6 months | |
Secondary | The change in renal function level at the end of the intervention | The health outcome indicator of management of renal disease by using the estimated Glomerular filtration rate(eGRF) . | To collect two-time point data by chart review. Those were before the intervention and the end of the the 6 weeks intervention | |
Secondary | The change Trajectory of renal function level from baseline to after intervention at 6 months and 1 year | The health outcome indicator of management of renal disease by using the estimated Glomerular filtration rate(eGRF) . | To collect three-time point data by chart review. Those were before the intervention, the end of the 6 weeks intervention, and after intervention at six months and 1 year | |
Secondary | The change in HbA1C level at the end of the intervention | The health outcome indicator of management of diabetes | To collect two-time point data by chart review. Those were before the intervention and the end of the the 6 weeks intervention | |
Secondary | The change Trajectory of HbA1C level from baseline to after the intervention at 3, 6, and 12 months | The health outcome indicator of management of diabetes | To collect four-time point data by chart review. Those were before the intervention, the end of the 6 weeks intervention, after the intervention at three months, after the intervention at six months, and after the intervention at twelve months | |
Secondary | The change in Triglycerides level at the end of the intervention | The health outcome indicator of management of lipid | To collect two-time point data by chart review. Those were before the intervention and the end of the six weeks intervention | |
Secondary | The change Trajectory of Triglycerides level from baseline to after the intervention at 3 , 6 and 12 months | The health outcome indicator of management of lipid | To collect four-time point data by chart review. Those were before the intervention, the end of the 6 weeks intervention, after the intervention at three months, after the intervention at six months, and after the intervention at twelve months. | |
Secondary | The change in Cholesterol level at the end of the intervention | The health outcome indicator of management of lipid | To collect two-time point data by chart review. Those were before the intervention and the end of the 6 weeks intervention | |
Secondary | The change Trajectory of Cholesterol level from baseline to after the intervention at 3, 6 and 12 months | The health outcome indicator of management of lipid | To collect two-time point data by chart review. Those were before the intervention, the end of the 6 weeks intervention, after the intervention at three months, after the intervention at six months, and after the intervention at twelve months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|